CRISPR Therapeutics Vertex Pharmaceuticals: Better Buy in 2026
Investors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Uncover creative ways to make money while consolidating debts, allowing you to pay off obligations faster and improve your financial situation.
27,644 articlesInvestors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
A high-profile shift at Base has changed the project’s direction. Jesse Pollak is stepping back from app leadership t...
At a key investor conference, Micron revealed strategic moves and market signals that could alter its trajectory. Her...
Tensions in the Middle East have traders eyeing crude prices. This article examines why analysts predict iran conflic...
CoreWeave stock gets headlines can spark investor interest, but smart portfolios look beyond headlines. This guide ex...
In 2026, MSTR stock has outpaced Bitcoin even as Strategy’s funding stack tests the durability of its preferreds. Inv...
The U.S. government imposed new restrictions on releasing a major AI model, triggering immediate market moves. Analys...
U.S. regulators have cleared broader access to Anthropic’s Mythos model after a brief regulatory stand-off over safet...
Publicly traded crypto firms rose 23% in the first half of 2026 while crypto assets declined 36%, widening the gap to...
Cogent’s Q4 2025 results show steady growth with improving margins and cautious guidance for 2026. This article inter...
A contrarian call on badly fallen stocks can pay off when the narrative shifts. This deep dive examines could beyond ...
Nvidia sits at a potential turning point, guided by a history of cycles tied to AI and data centers. This article unf...